Shop/Compare
Retatrutide vs Tirzepatide
Retatrutide and tirzepatide are both weekly incretin peptides, but they differ in how many receptors they hit. Tirzepatide is a dual GLP-1/GIP agonist; retatrutide adds a third target — the glucagon receptor — making it a triple agonist. Here is how they compare on mechanism, dosing cadence, and half-life.
Retatrutide
Triple agonist — GLP-1 / GIP / glucagon
Triple incretin agonist — the newest and broadest of the three, still investigational.
View Retatrutide →Tirzepatide
Dual agonist — GLP-1 / GIP
Dual incretin agonist — combines two receptor pathways in one molecule.
View Tirzepatide →Side by side
| Retatrutide | Tirzepatide | |
|---|---|---|
| Receptor targets | GLP-1, GIP, and glucagon (GCG) receptors | GLP-1 and GIP receptors |
| Mechanism class | Triple incretin agonist — the newest and broadest of the three, still investigational. | Dual incretin agonist — combines two receptor pathways in one molecule. |
| Typical research cadence | Once-weekly subcutaneous in most research protocols. | Once-weekly subcutaneous in most research protocols. |
| Approx. half-life | ~6 days (supports weekly dosing) | ~5 days (supports weekly dosing) |
| Domain | Metabolic | Metabolic |
The short version
The practical distinction is receptor breadth: tirzepatide (dual) versus retatrutide (triple, plus glucagon). Both are handled the same way in the lab — weekly subcutaneous dosing after reconstitution — so the choice for a research protocol comes down to which receptor profile you are studying, not the mechanics of use.
Dosage calculator
Convert any target dose into exact syringe units for your vial.
Lab testing & COAs
How every lot is verified — third-party HPLC, ≥98% purity.
Protocols
Goal-oriented stacks mapped to specific compounds.
Frequently asked questions
What is the difference between retatrutide and tirzepatide?
Tirzepatide is a dual agonist that activates the GLP-1 and GIP receptors. Retatrutide is a triple agonist that adds a third target, the glucagon (GCG) receptor. Retatrutide is the newer and still-investigational of the two; both are dosed once weekly in most research protocols.
Are retatrutide and tirzepatide dosed the same way?
Both are typically reconstituted and administered subcutaneously once per week in research settings, but the milligram amounts differ by compound and protocol. Use the dosage calculator to convert a target dose into syringe units for the specific vial you have.
Which is newer, retatrutide or tirzepatide?
Retatrutide is the newer molecule and remains investigational. Tirzepatide has a longer research and clinical track record as a dual GLP-1/GIP agonist.
Disclaimer
This comparison describes receptor mechanism and handling for research context only. It is not medical advice and makes no claim of safety or efficacy. All compounds are sold for research use only. Consult a licensed physician before using any peptide compound outside controlled research.